177 related articles for article (PubMed ID: 31361922)
1. Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Carr A; Kerr SJ; Richardson R; Ebeling P; Pocock N; Rojas J; Martinez E; Hoy J;
J Bone Miner Res; 2019 Dec; 34(12):2192-2197. PubMed ID: 31361922
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
[TBL] [Abstract][Full Text] [Related]
4. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
5. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Rasmussen TA; Jensen D; Tolstrup M; Nielsen US; Erlandsen EJ; Birn H; Østergaard L; Langdahl BL; Laursen AL
PLoS One; 2012; 7(3):e32445. PubMed ID: 22479327
[TBL] [Abstract][Full Text] [Related]
6. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
Mwasakifwa GE; Amin J; White CP; Center JR; Kelleher A; Boyd MA
HIV Med; 2020 Sep; 21(8):492-504. PubMed ID: 32573910
[TBL] [Abstract][Full Text] [Related]
7. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
[TBL] [Abstract][Full Text] [Related]
8. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
[TBL] [Abstract][Full Text] [Related]
9. Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.
Moore AEB; Burns JE; Sally D; Milinkovic A; Krokos G; John J; Rookyard C; Borca A; Pool ERM; Tostevin A; Harman A; Dulnoan DS; Gilson R; Arenas-Pinto A; Cook GJR; Saunders J; Dunn D; Blake GM; Pett SL
AIDS; 2024 Mar; 38(4):521-529. PubMed ID: 38061030
[TBL] [Abstract][Full Text] [Related]
10. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
11. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks.
Tebas P; Kumar P; Hicks C; Granier C; Wynne B; Min S; Pappa K
AIDS; 2015 Nov; 29(18):2459-64. PubMed ID: 26355674
[TBL] [Abstract][Full Text] [Related]
12. Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIV.
Hsieh E; Fraenkel L; Xia W; Hu YY; Han Y; Insogna K; Yin MT; Xie J; Zhu T; Li T
Osteoporos Int; 2015 Mar; 26(3):1035-44. PubMed ID: 25224293
[TBL] [Abstract][Full Text] [Related]
13. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
14. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
15. Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.
Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid I; Gamble GD; Grey A
J Bone Miner Res; 2019 Jul; 34(7):1248-1253. PubMed ID: 30870576
[TBL] [Abstract][Full Text] [Related]
16. Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.
Negredo E; Diez-Pérez A; Bonjoch A; Domingo P; Pérez-Álvarez N; Gutierrez M; Mateo G; Puig J; Echeverría P; Escrig R; Clotet B
J Antimicrob Chemother; 2015 Jul; 70(7):2104-7. PubMed ID: 25769303
[TBL] [Abstract][Full Text] [Related]
17. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Human Immunodeficiency Virus Infection With Tenofovir Disoproxil Fumarate-Containing Antiretrovirals Maintains Low Bone Formation Rate, But Increases Osteoid Volume on Bone Histomorphometry.
Ramalho J; Martins CSW; Galvão J; Furukawa LN; Domingues WV; Oliveira IB; Dos Reis LM; Pereira RM; Nickolas TL; Yin MT; Eira M; Jorgetti V; Moyses RM
J Bone Miner Res; 2019 Sep; 34(9):1574-1584. PubMed ID: 31269294
[TBL] [Abstract][Full Text] [Related]
19. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
Bloch M; Tong WW; Hoy J; Baker D; Lee FJ; Richardson R; Carr A;
HIV Med; 2014 Jul; 15(6):373-80. PubMed ID: 24460797
[TBL] [Abstract][Full Text] [Related]
20. Observational Study to Evaluate the Effect of Epidural Steroid Injection on Bone Mineral Density and Bone Turnover Markers.
Jain A; Gupta P; Chaurasia R; Singh M; Pandey S
Pain Physician; 2020 Sep; 23(5):E517-E524. PubMed ID: 32967402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
